Can-Fite reports Phase II liver cancer patient alive and cancer-free after ten years on Namodenoson
Can-Fite says a patient with advanced hepatocellular carcinoma who had a complete response in its Phase II Namodenoson study has reached ten-year survival, though the company stresses the case is anecdotal.
Can-Fite BioPharma said on 9 November 2026 that a patient with advanced hepatocellular carcinoma (HCC) has survived ten years and remains cancer-free. The patient had achieved a complete response in the company's completed Phase II study of Namodenoson.
The company presents the result as a single-patient observation. It is anecdotal, and Can-Fite says treatment-specific efficacy will be judged only in the planned analysis of its pivotal trial, not on the basis of individual cases.
Namodenoson is currently being tested in a blinded pivotal Phase III trial in advanced HCC patients with Child-Pugh B7 cirrhosis. On 2 September 2026, the company announced that pooled survival data in the study looked longer than the trial design had assumed.
Because the trial remains blinded, those pooled figures cannot be attributed to Namodenoson rather than to the control arm. Can-Fite said it is considering bringing forward an interim analysis.
Why it matters
- A single complete responder after ten years is anecdotal and does not substitute for controlled Phase III evidence of efficacy.
- Pooled survival in the blinded trial is not treatment-specific, so it should not be read as a signal of benefit for Namodenoson.
- Any decision to bring forward the interim analysis would be worth watching, as it would affect the timing of efficacy data and potential filing plans.
Company's press release (SEC filing): Can-Fite BioPharma Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
